IDS and mucopolysaccharidosis type 2: The Denali team has shown significant therapeutic effects with the TV-based technology, successfully targeting lysosomal enzyme iduronate 2-sulfatase (IDS) DNL310 (ClinicalTrials.gov:NCT05371613) to treat Hunter syndrome (or MPS II)148 and N-sulfoglucosamine sulfohydrolase (SGSH) DNL126 to treat neuropathic and systemic forms of the Sanfilippo syndrome A (ClinicalTrials.gov:NCT06181136).